Диссертация (1154305), страница 30
Текст из файла (страница 30)
Sahnoun, K. Zeghal // RevNeurol (Paris). – 2017 Mar;173(3):159-163.133.Berman, E. Utilization of antiepileptic drugs in Israel / E. Berman, E.Marom, D. Ekstein, I. Blatt, S. Eyal // Epilepsy Behav. – 2016 Aug;61:82-5. doi:10.1016/j.yebeh.2016.05.004. Epub 2016 Jun 23.134.Bergman, U. Drug utilization 90%--a simple method for assessing the qualityof drug prescribing / U. Bergman, C. Popa, Y. Tomson, B. Wettermark, T.R.Einarson, H.
Aberg, F. Sjoqvist // Eur J Clin Pharmacol. – 1998 Apr. – Vol. 54. –№ 2. – P. 113-118. – URL: http://www.ncbi.nlm.nih.gov/pubmed/9626914?ordinalpos=12&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum.135.Besag, F.M. Clinical efficacy of perampanel for partial-onset and primarygeneralized tonic-clonic seizures / F.M.
Besag, P.N. Patsalos // Neuropsychiatr DisTreat. – 2016. – May 17;12:1215-20.136.Blackford, M.G. Valproic Acid and topiramate induced hyperammonemicencephalopathy in a patient with normal serum carnitine / M.G. Blackford, S.T.Do, T.C. Enlow, M.D. Reed // J. Pediatr. Pharmacol. Ther. – 2013 Apr. – Vol. 18.– № 2. – P. 128-136.
doi: 10.5863/1551-6776-18.2.128.]137.Brodie, M.J. Enzyme induction with antiepileptic drugs: cause for concern?/ M.J. Brodie, S. Mintzer, A.M. Pack, B.E. Gidal, C.J. Vecht, D. Schmidt //Epilepsia. – 2013 Jan;54(1):11-27. doi: 10.1111/j.1528-1167.2012.03671.x. Epub2012 Sep 27.138.Brusturean-Bota, E. Impact of CYP2C9 genetic polymorphisms on valproatedosage, plasma concentrations of valproate and clinical response to valproate / E.183Brusturean-Bota, A.P. Trifa, C.A. Coadă [et al.] // Hum. Veterinary Med. Int. J.Bioflux Soc. – 2013. – Vol. 5, № 3.
– P. 94-98.139.Camfield, P. Monitoring for adverse effects of antiepileptic drugs / P.Camfield, C. Camfield // Epilepsia. – 2006. – Vol. 47, Suppl. 1. – P. 31-34140.Canevini, M.P. Relationship between adverse effects of antiepileptic drugs,number of coprescribed drugs, and drug load in a large cohort of consecutivepatients with drug-refractory epilepsy / M.P. Canevini, G.
De Sarro, C.A.Galimberti, G. Gatti, L. Licchetta, A. Malerba, G. Muscas, A. La Neve, P. Striano,E. Perucca // Epilepsia. – 2010. May;51(5):797-804.141.Chang, L. Economic burden of disease studies in patients with epilepsy / L.Chang, B.Y. Zhu, J. Chang, S.X. Feng, G. Zhou // Zhonghua Yu Fang Yi Xue ZaZhi. – 2012 Dec;46(12):1084-7.142.Chang, Y. Correlation of the UGT1A4 gene polymorphism with serumconcentration and therapeutic efficacy of lamotrigine in Han Chinese of NorthernChina / Y. Chang, L.Y. Yang, M.C. Zhang, S.Y.
Liu // Eur. J. Clin. Pharmacol. –2014. – Vol. 70. – № 8. – P. 941-946.143.Chaudhary, N. Frequencies of CYP2C9 polymorphisms in North Indianpopulation and their association with drug levels in children on phenytoinmonotherapy / N. Chaudhary, M. Kabra, S. Gulati, Y.K. Gupta, R.M. Pandey, B.D.Bhatia // BMC Pediatr. – 2016. May 14;16:66.144.Chbili, C. Effects of EPHX1 and CYP3A4*22 genetic polymorphisms oncarbamazepine metabolism and drug response among Tunisian epileptic patients /C. Chbili, N. Fathallah, A.
Laouani, M. Nouira, A. Hassine, S. Ben Amor, S. BenAmmou, C. Ben Salem, S. Saguem // J Neurogenet. – 2016 Mar;30(1):16-21.145.Chen, S.Y. Antiepileptic drug treatment patterns and economic burden ofcommercially – insured patients with refractory epilepsy with partial onset seizuresin the United States / S.Y. Chen, N. Wu, L.
Boulanger, P. Sacco // J Med Econ.2013; 16(2):240-8.184146.Chu, X.M. Influence of UDP-glucuronosyltransferase polymorphisms onvalproic acid pharmacokinetics in Chinese epilepsy patients / X.M. Chu, L.F.Zhang, G.J. Wang, S.N. Zhang, J.H. Zhou, H.P. Hao // Eur. J. Clin. Pharmacol. –2012.
– Vol. 68. – № 10. – P. 1395-1401.147.Conroy, S. Survey of unlicensed and off label drug use in paediatric wardsin European countries. European Network for Drug Investigations in Children / S.Conroy, I. Choonara, P. Impicciatore, et al. // Br Med J. – 2000;320:79-82.148.Cramer, J.A. Non-interventional surveillance study of adverse events inpatients with epilepsy / J.A.
Cramer, B. Steinborn, P. Striano, L. Hlinkova, A.Bergmann, I. Bacos, C. Baukens, S. Buyle // Acta Neurol Scand. – 2011Jul;124(1):13-21.149.Daly, A.K. Direct-to-consumer pharmacogenomic testing assessed in a US-based study / A.K. Daly // J R Coll Physicians Edinb. 2014;44(3):212-3.150.deKinderen, R.J. From clinically relevant outcome measures to quality oflife in epilepsy: A time trade-off study / R.J. deKinderen, B.F. Wijnen, G. vanBreukelen, D. Postulart, M.H. Majoie, A.P. Aldenkamp, S.M. Evers // EpilepsyRes. – 2016 Sep;125:24-31.151.Depondt, C.
Epilepsy pharmacogenetics: science or fiction? / C. Depondt //Med Sci (Paris). – 2013. Feb;29(2):189-93.152.Einarson T.R. Drug-related hospital admissions // Ann. Pharmacother. –1993. – Vol. 27. – P. 832–840.153.URL:Epilepsy in the WHO European Region: fostering epilepsy care in Europe. –http://www.who.int/mental_health/neurology/epilepsy/euro_report.pdf(Дата обращения: 09.10.2016)154.Franco,V.CYP2C9polymorphismsandphenytoinmetabolism:implications for adverse effects / V.
Franco, E. Perucca // Expert Opin Drug MetabToxicol. – 2015;11(8):1269-79.155.Franco, V. Off-label prescribing of antiepileptic drugs in pharmacoresistantepilepsy: a cross-sectional drug utilization study of tertiary care centers in Italy /185V. Franco, M.P. Canevini, G. Capovilla, G. De Sarro, C.A. Galimberti, G. Gatti,R. Guerrini, A. La Neve, E. Rosati, L.M. Specchio, S. Striano, P.
Tinuper, E.Perucca // CNS Drugs. – 2014 Oct;28(10):939-49. doi: 10.1007/s40263-014-01898.156.French, J.A. New generation antiepileptic drugs: what do they offer in termsof improved tolerability and safety? / J.A. French, D.M. Gazzola // Ther. Adv. DrugSaf. – 2011. – № 2. – P. 141–158. doi: 10.1177/2042098611411127.157.Gijsen, R. Frequency of ill-founded off-label prescribing in Dutch generalpractice / R. Gijsen, H. Jochemsen, L. van Dijk, P. Caspers // PharmacoepidemiolDrug Saf. 2009 Jan;18(1):84-91.158.Girgin, M.C. Emergency department visits caused by adverse drug reactions:results of aTurkish university hospital / M.C. Girgin, S.
Yanturali, M.A. Arici, N.Çolak Oray, Ö. Doylan, Y. Demiral, Y. Tunçok // Turk J Med Sci. – 2016. – Jun23;46(4):945-52.159.Glauser, T.A. Biomarkers for antiepileptic drug response / T.A. Glauser //Biomark Med. 2011 Oct;5(5):635-41.160.Guidelines for therapeutic monitoring on antiepileptic drugs: CommissiononAntiepileptic Drugs, International League Against Epilepsy // Epilepsia 1993; 34:585-587.161.Gulcebi, M.I. The relationship between UGT1A4 polymorphism and serumconcentration of lamotrigine in patients with epilepsy / M.I. Gulcebi, A.Ozkaynakci, M.Z.
Goren, R.G. Aker, C. Ozkara, F.Y. Onat // Epilepsy Res. – 2011.– Vol. 95. – № 1-2. – P. 1-8.162.Gupta, V. An Analytical Study to Correlate Serum Levels of Levetiracetamwith Clinical Course in Patients with Epilepsy / V. Gupta, K. Gupta, G. Singh, S.Kaushal // J. Neurosci.
Rural. Pract. – 2016 Dec;7(Suppl 1):S31-S36.163.Hauser, W.A. Incidence of epilepsy and unprovoked seizures in Rochester,Minnesota: 1935–1984 / W.A. Hauser, J.F. Annegers, L.T. Kurland // Epilepsia. –1993. – Vol. 34, № 3. – P. 453-468.186164.Haerian, B.S. Association of ABCB1 gene polymorphisms and theirhaplotypes with response to antiepileptic drugs: a systematic review and metaanalysis / B.S. Haerian, K.S. Lim, C.T. Tan, A.A. Raymond, Z.
Mohamed //Pharmacogenomics. – 2011. – May;12(5). P.713-725.165.Haerian, B.S. ABCB1 C3435T polymorphism and the risk of resistance toantiepileptic drugs in epilepsy: a systematic review and meta-analysis / B.S.Haerian, H. Roslan, A.A. Raymond, C.T. Tan, K.S. Lim, S.Z. Zulkifli, E.H.Mohamed, H.J. Tan, Z. Mohamed // Seizure. – 2010. – Jul;19(6). – P.339-346.166.Hilgers, A., Schaefer M. Systematic adverse drug reaction monitoring ofpatients under newer antiepileptic drugs using routine clinical data of inpatients.
/A. Hilgers, M. Schaefer // Drugs Real World Outcomes. – 2016 May 25;3(2):209221.167.Ho, P.C. Influence of CYP2C9 genotypes on the formation of a hepatotoxicmetabolite of valproic acid in human liver microsomes / P.C. Ho, F.S. Abbott, U.M.Zanger // Pharmacogenomics J. – 2003. – Vol. 3, № 6. – P. 335-342.168.Hollingworth, S.A.
Antiepileptic drugs in Australia: 2002-2007 / S.A.Hollingworth, M.J. Eadie // Pharmacoepidemiol. Drug Saf. – 2010 Jan;19(1):82-9.doi: 10.1002/pds.1871.169.Hong, Z. Economic burden of epilepsy in a developing country: aretrospective cost analysis in China / Z. Hong, B. Qu, X.T. Wu, T.H. Yang, Q.Zhang, D. Zhou // Epilepsia.
– 2009 Oct;50(10):2192-8.170.Hung, C.C. Dosage recommendation of phenytoin for patients with epilepsywith different CYP2C9/CYP2C19 polymorphisms / C.C. Hung, C.J. Lin, C.C.Chen, C.J. Chang, H.H. Liou // Ther Drug Monit. – 2004. - Oct;26(5):534-40.171.Hwang, H. Long-term effectiveness of ethosuximide, valproic acid, andlamotrigine in childhood absence epilepsy / H.
Hwang, H. Kim, S.H. Kim, S.H.Kim, B.C. Lim, J.H. Chae, J.E. Choi, K.J. Kim, Y.S. Hwang // Brain Dev. –2012;34:344-348.187172.Inoue, K. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsypatients / K. Inoue, E. Suzuki, R.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
